Author + information
Patients receiving prosthetic heart valves have well documented additional lifetime costs. This study models the differences in the lifetime cost of health care consumed by prosthesis type: (Stented Tissue (ST) or Mechanical Valve (MV)).
The model estimates cost for On–X Life Technologies MV vs. ST with standard surgical aortic valve replacement at re–operation (between 10 and 25 years) assuming 25 year survival and 3% medical inflation. Complication event rate estimates were obtained from peer reviewed journals by prosthesis type. Clinical events include: initial valve surgery, thrombotic events, bleeding events, warfarin and monitoring, echo monitoring, paravalular leak, endocarditis, pacemaker insertion following valve surgery, and re–operation due to structural valve disease.
The chart shows lifetime healthcare cost curves between using ST vs. MV and annual savings. Total costs are estimated to be $183,600 for ST versus $124,200 using MV: a $59,400 (~48%) lifetime cost saving for using MV for initial implantation. The Savings Curve indicates a small annual savings for MV for the first decade, and increasing after year 10 due to higher costs associated with reoperation.
This study demonstrates lifetime savings of $59,400 by implanting MV vs. ST. Using MV for the estimated 20,000 ST valve surgeries performed annually in the U.S. in patients below age 65 would potentially result in nearly $1.2 billion lifetime reduction in healthcare expenditures.
Poster Sessions, Expo North
Sunday, March 10, 2013, 3:45 p.m.–4:30 p.m.
Session Title: Valvular Heart Disease: Clinical VI – Prosthetic Valve
Abstract Category: 31. Valvular Heart Disease: Clinical
Presentation Number: 1241–82
- 2013 American College of Cardiology Foundation